Method for creating a macular/retinal degeneration animal model

Tech ID: 28953 / UC Case 2017-987-0

Brief Description

Researchers at UCI have developed an animal model that mimics the onset and progression of age-related macular degeneration, an incurable disease that is the fourth-leading cause of blindness globally. The model serves as a means for testing the efficacy of possible treatments and cures.

Full Description

Age-related macular degeneration (AMD) is a retinal disease which affects nearly 6.2 million people, making it the fourth-leading cause of blindness globally. AMD occurs when extracellular lipids and proteins, called drusen, are deposited in the macula (center of the retina). Over time, the drusen aggregate and eventually vascularize, leading to distortion in and ultimately loss of vision. There is currently no known cure for AMD. Studies into the treatment and pathology of AMD typically rely on human clinical trials and in vitro models, respectively. Human trials are often limited in sample size and are expensive and possibly dangerous to conduct. In vitro models do not account for the cellular architecture and signaling involved in the progression of AMD, and are therefore limited in accuracy.

The researchers at UCI have developed an entirely in vivo model of AMD utilizing New Zealand white rabbits. By carefully subjecting the rabbits to various external stimuli over a period of several weeks, they were able to induce symptoms of AMD including retinal inflammation and drusen deposition. As the stage and severity of the disease are controlled by the extent of exposure to the external stimuli, researchers can monitor not only the onset but also the progression of AMD in the rabbits, making them a useful model for testing the efficacy of proposed preventions and methods.

Suggested uses

For testing diagnostic and pharmaceutical interventions for age-related macular degeneration and other degenerative retinal diseases

Advantages

  • Inexpensive and simple: The proposed rabbit model is less expensive and complicated to execute than human clinical trials, which require securing and compensating licensed physicians and social workers, as well as suitable volunteers.
  • Safe: Clinical trials in general are also safer to perform on less sentient creatures than humans.
  • Accurate: The in vivo model presented here is more accurate than previous in vitro platforms.

Patent Status

Patent Pending

State Of Development

In the experimental stage; the model has been validated with one rabbit so far and is currently being tested in several others.

Contact

Learn About UC TechAlerts - Save Searches and receive new technology matches

Other Information

Categorized As

  • AN INTEGRAL PART OF
  • Institute for Innovation Logo
  • Institute for Innovation Logo

University of California, Irvine Invention Transfer Group
5141 California Avenue, Suite 200, Irvine,CA 92697-7700
Tel: 949.824.2683 | Fax: 949.824.3880
www.ota.uci.edu | ota@uci.edu

© 2017, The Regents of the University of California
Terms of use | Privacy Notice